1
Clinical Trials associated with I131-tumor necrosis factor monoclonal antibodyOpen-label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme
RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out." This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer.
PURPOSE: This trial is studying the safety and radiation distribution of Cotara® in patients with recurrent glioblastoma multiforme.
100 Clinical Results associated with I131-tumor necrosis factor monoclonal antibody
100 Translational Medicine associated with I131-tumor necrosis factor monoclonal antibody
100 Patents (Medical) associated with I131-tumor necrosis factor monoclonal antibody
100 Deals associated with I131-tumor necrosis factor monoclonal antibody